Merck & Co., Inc. (ETR: 6MK)
Germany
· Delayed Price · Currency is EUR | Market Cap | 265.18B |
| Revenue (ttm) | 58.31B |
| Net Income (ttm) | 12.82B |
| Shares Out | n/a |
| EPS (ttm) | 5.03 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | Sep 16, 2024 |
| Volume | 712 |
| Open | 104.80 |
| Previous Close | 105.40 |
| Day's Range | 103.80 - 105.00 |
| 52-Week Range | 91.00 - 125.60 |
| Beta | 0.40 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 31, 2024 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M−M−R II, Variv... [Read more]
Financial Performance
In 2023, Merck & Co.'s revenue was $60.12 billion, an increase of 1.40% compared to the previous year's $59.28 billion. Earnings were $365.00 million, a decrease of -97.49%.
Financial numbers in USD Financial StatementsNews
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2169721099-455715866b8f4867a241844c1e92f89a.jpg)
Top Stock Movers Now: Boeing, Palantir Technologies, Merck, and More
U.S. equities rallied back from last week's selloff at midday as investors put more money into blue chip stocks.
BA Reaches Union Deal, COST Price Target Hike, MRK Down as SMMT Rallies
A tentative deal between Boeing (BA) and the International Aerospace Machinists union could avoid a strike. Costco (COST) receives another price target hike.
Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday
U.S. stocks were higher, with the Dow Jones index gaining around 400 points on Monday. Shares of Terns Pharmaceuticals, Inc . (NASDAQ: TERN) rose sharply in today's pre-market trading session. The co...
Bitcoin, Ethereum, Dogecoin Rebound From Friday's Drop; Boeing Shares Climb 3% Pre-Market After Reaching Tentative Deal With Workers' Union to Avert Strike - Top Headlines Today While US Slept
Crypto Ripple Expands XRP Ledger With Ethereum-Compatible Smart Contracts Via Sidechain Bitcoin, Ethereum Need New Catalyst For ‘Enhanced Retail Engagement,’ JPMorgan Says Top Crypto Analyst Rules Out...
Market rally led by tech and consumer cyclical giants: Nvidia and Amazon soar
Dynamic Gains in Technology and Consumer Cyclicals Diving into today’s market activity reveals a robust uptrend led by the technology and consumer cyclical sectors. Powered by standout performances fr...
Summit Therapeutics’ stock pops as lung-cancer treatment beats Merck blockbuster in late-stage trial
Shares of Summit Therapeutics Inc. jumped more than 30% premarket on Monday after the biotech company released late-stage trial data showing that its experimental lung-cancer treatment topped Merck’s ...
Stocks making the biggest premarket moves: Boeing, Dell, Merck and more
These are the stocks posting the largest moves in the premarket.
Biotech Stocks: Lung Cancer Treatment Outflanks Merck's Keytruda
Summit shares jumped Monday after positive late-stage indications vs. Merck's Keytruda.
Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half
Summit Therapeutics shared Phase 3 HARMONi-2 trial data of ivonescimab, showing significant improvement in ... Full story available on Benzinga.com
Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half
Sunday, Summit Therapeutics Inc. SMMT released data from the primary analysis of the Phase 3 HARMONi-2 trial of ivonescimab conducted in China, sponsored by collaboration partner Akeso, Inc.
Summit stock soars as lung cancer drug beats Merck’s Keytruda in late-stage trial
Merck Stock Falls After Rival Beats Keytruda Cancer Drug in Trial
Merck, Daiichi post mid-stage data for novel lung cancer drug
Buy 3 September Dogs Of The Dow; Watch 6
"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors
Eighty-eight Corporate Leaders Endorse Harris For Continued 'Strength' Of Democracy, Economy
Letter signers include Yelp, Snap and Box CEOs, media empire heir James Murdoch, former CEOs of PepsiCo, Lyft and Merck
Why Did Merck Stock Rise 65%?
Merck stock (NYSE: MRK) has gained over 65% in value since early January 2021 – jumping from levels of $70 then to around $115 now – vs. an increase of about 50% for the S&P 500 over this period.
What's Going On With Merck Shares Thursday?
Merck stock is trading higher on ... Full story available on Benzinga.com
What's Wrong With Merck's Stock?
Is the healthcare stock an underrated buy right now?
Merck to Present Survival Data and New Research on 10 Investigational or Approved Medicines at ESMO Congress 2024
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data for four approved medicines and six pipeline candidates in more than 20 types of cancer will be p...
Merck to Present Survival Data and New Research on 10 Investigational or Approved Medicines at ESMO Congress 2024
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data for four approved medicines and six pipeline candida...
Merck and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret for the Treatment of Diabetic Macular Edema
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and EyeBio, a wholly-owned subsidiary of Merck & Co., Inc., Rahway, N.J., USA, today announced the initiation of the Phase 2b/3...
Merck and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™ for the Treatment of Diabetic Macular Edema
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and EyeBio, a wholly-owned subsidiary of Merck & Co., Inc., Rahway, N.J., USA, today announced t...
Merck's Death Cross Vs. Gilead's Golden Cross: Pharma Giants Diverge On Wall Street
Merck & Co. (NYSE: MRK) and Gilead Sciences Inc. (NYSE: GILD) are two pharmaceutical heavyweights whose stocks tell very different stories . Rahway, New Jersey-based Merck just flashed a Death Cross...
Merck's Death Cross Vs. Gilead's Golden Cross: Pharma Giants Diverge On Wall Street
Merck & Co. MRK and Gilead Sciences Inc. GILD are two pharmaceutical heavyweights whose stocks tell very different stories.